Amelioration of Hyperglycemia in Streptozotocin-Induced Diabetic Rats Receiving a Marginal Mass of Islet Grafts by Troglitazone, an Oral Antidiabetic Agent

Pancreas ◽  
1996 ◽  
Vol 13 (4) ◽  
pp. 381-387 ◽  
Author(s):  
Tetsu Nagai ◽  
Yohichi Yasunami ◽  
Naoki Nagata ◽  
Shinichiroh Ryu ◽  
Junko Ono ◽  
...  
Keyword(s):  
Diabetic Rats ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

Proposal for the administration of metformin in patients with chronic kidney disease

2012 ◽  
Vol 153 (39) ◽  
pp. 1527-1535 ◽  
Author(s):  
Zoltán Balogh ◽  
János Mátyus
Keyword(s):  
Lactic Acidosis ◽  
Chronic Renal Disease ◽  
Antidiabetic Agent ◽  
First Line ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Cardiovascular Morbidity And Mortality ◽  
Glomerular Filtrate ◽  
Life Threatening

Metformin is the first-line, widely used oral antidiabetic agent for the management of type 2 diabetes. There is increasing evidence that metformin use results in a reduction in cardiovascular morbidity and mortality, and might have anticancer activity. An extremely rare, but potentially life-threatening adverse effect of metformin is lactic acidosis, therefore, its use is traditionally contraindicated if the glomerular filtrate rate is below 60 mL/min. However, lactic acidosis is always associated with acute events, such as hypovolemia, acute cardiorespiratory illness, severe sepsis and acute renal or hepatic failure. Furthermore, administration of insulins and conventional antihyperglycemic agents increases the risk of severe hypoglycemic events when renal function is reduced. Therefore, the magnitude of the benefit of metformin use would outweigh potential risk of lactic acidosis in moderate chronic renal disease. After reviewing the literature, the authors give a proposal for the administration of metformin, according to the calculated glomerular filtrate rate. Orv.Hetil., 2012, 153, 1527–1535.

scholarly journals Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)-N-(trans-4-isopropylcyclohexane-carbonyl)-d -phenylalanine (A-4166)

1997 ◽  
Vol 120 (1) ◽  
pp. 137-145 ◽  
Author(s):  
Takao Ikenoue ◽  
Megumi Akiyoshi ◽  
Shoji Fujitani ◽  
Kyoko Okazaki ◽  
Nobuo Kondo ◽  
...  
Keyword(s):  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

scholarly journals Effects of HOE 490, a new oral antidiabetic agent, on platelet aggregation

1989 ◽  
Vol 49 ◽  
pp. 328
Author(s):  
Mikio Omosu ◽  
Shunsuke Tsutsumi ◽  
Ryuji Yajima ◽  
Shoryo Hayashi
Keyword(s):  
Platelet Aggregation ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

Successful Pancreas Transplantation From a Deceased Donor Intoxicated With Oral Antidiabetic Agent: A Case Report

2015 ◽  
Vol 47 (8) ◽  
pp. 2404-2406 ◽  
Author(s):  
C. Rodríguez-Villar ◽  
I. Conget ◽  
J. Ferrer-Fàbrega ◽  
D. Paredes ◽  
A. Ruíz ◽  
...  
Keyword(s):  
Case Report ◽  
Pancreas Transplantation ◽  
Deceased Donor ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic

scholarly journals Effects of Tungstate, a New Potential Oral Antidiabetic Agent, in Zucker Diabetic Fatty Rats

Diabetes ◽  
2001 ◽  
Vol 50 (1) ◽  
pp. 131-138 ◽  
Author(s):  
M. C. Munoz ◽  
A. Barbera ◽  
J. Dominguez ◽  
J. Fernandez-Alvarez ◽  
R. Gomis ◽  
...  
Keyword(s):  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Zucker Diabetic Fatty Rats

Effect of the new oral antidiabetic agent (−)-BM 13.0913.Na on insulin resistance in lean and obese zucker rats

Metabolism ◽  
1995 ◽  
Vol 44 (5) ◽  
pp. 577-583 ◽  
Author(s):  
R. Apweiler ◽  
H.F. Kühnle ◽  
G. Ritter ◽  
R. Schell ◽  
P. Freund
Keyword(s):  
Insulin Resistance ◽  
Zucker Rats ◽  
Antidiabetic Agent ◽  
Oral Antidiabetic Agent ◽  
Oral Antidiabetic ◽  
Obese Zucker Rats
Sign in / Sign up

Export Citation Format

Share Document